GHK Peptide Dosage in the Research Literature

GHK peptide dosage in published research spans nine orders of magnitude across five administration routes — from picomolar cell culture concentrations to milligram-per-kilogram intranasal doses in aged mouse models. This page documents the administration context from the peer-reviewed literature. GHK-Cu is not an FDA-approved drug. All dosing information below describes what was administered in specific research models, not a recommendation for any use in humans.

Published studies have employed five distinct routes of administration for GHK-Cu:

Topical cream/serum (human clinical trials): The most clinically documented route. Concentrations from 0.01% to 1% GHK-Cu in topical formulations. The 12-week human trial used a topical cream at an unspecified concentration ^[2]. The nanolipid carrier study achieved 55.8% wrinkle volume reduction using this route over 8 weeks ^[5]. Skin penetration data confirm therapeutically relevant dermal accumulation: permeability coefficient 2.43 x 10^-4 cm/h, stratum corneum accumulation 438-fold over baseline ^[6].

Intranasal (mouse cognitive studies): 15 mg/kg daily (containing 2.1 mg/kg copper component) in 20-month-old aged mice ^[7]; 15 mg/kg three times weekly for 12 weeks in 5xFAD Alzheimer's model mice ^[18]. This route achieved CNS-accessible effects without validated systemic pharmacokinetics.

Intraperitoneal (mouse pulmonary and inflammation studies): 2.6, 26, and 260 μg/mL/day in the bleomycin pulmonary fibrosis model ^[11]; 0.2, 2, and 20 μg/g/day on alternate days in the cigarette smoke emphysema model ^[12]; 2 and 20 mg/kg in the silicosis model ^[20].

Scaffold surface coating (in vitro tissue engineering): 1 mM GHK-Cu coating on poly(ε-caprolactone)/collagen/chitosan scaffolds improved fibroblast viability and demonstrated antibacterial activity versus E. coli and S. aureus within 1 hour ^[21].

Liposomal formulation (topical, enhanced delivery): GHK-Cu liposomes applied topically to scald wounds in mice accelerated healing by day 14 post-injury and increased endothelial proliferation by 33.1% over free GHK-Cu ^[15].

Topical formulation studies used concentrations ranging from 0.01% to 1% GHK-Cu in cream and serum vehicles. In vitro cell culture experiments used picomolar to micromolar concentrations to observe fibroblast response — maximum collagen stimulation at 10^-9 M (1 nanomolar), with detectable stimulation beginning at 10^-12 M (1 picomolar) ^[1]. The GHK/5-aminolevulinic acid hair growth trial used 50–100 mg/mL in topical formulation over 6 months ^[10]. Human mesenchymal stem cell cultures used 1–500 ng/mL GHK in medium (no cytotoxicity across this range) ^[16]. The GHK-Cu eye cream achieving wrinkle depth reduction was in the 0.01–1% range for topical use ^[5].

Precise plasma half-life data for systemically administered GHK-Cu in animal models is limited in the published literature. No validated pharmacokinetic parameters (T1/2, Cmax, AUC) for injectable or systemic routes have been published in peer-reviewed sources. Topical penetration studies provide the most quantitative PK-adjacent data: in human ex vivo skin, the stratum corneum forms a depot with gradual release into the dermis — a sustained 48-hour permeation profile ^[6]. For the intranasal route, two preprint studies document efficacy in mouse models at 15 mg/kg but do not report plasma concentration-time profiles ^[7][18]. The absence of validated systemic PK data is a recognized gap in the current GHK-Cu literature.

Published research protocols vary considerably by model and objective. Most human-applied studies used once or twice-daily topical application for 8–12 weeks ^[2][5]. The 6-month hair growth trial also used daily topical application ^[10]. Systemic injection studies in rodent pulmonary models used alternate-day intraperitoneal administration ^[12]. The intranasal cognitive studies used either daily administration ^[7] or three times weekly ^[18]. No published human study has formally characterized dose frequency response for GHK-Cu at any systemic route.

GHK-Cu has unfavorable physicochemical properties for passive skin penetration: MW 403.9 Da as the copper complex, clogP -2.24 (hydrophilic) ^[5]. Palmitoylation (Pal-GHK) and liposomal encapsulation improve dermal delivery. Formulation chemistry studies indicate strong acid actives (AHAs, BHAs) and ascorbic acid may reduce copper peptide stability in solution by competing for copper coordination — the clinical significance of these interactions in topical use is not fully established in randomized trials. Copper complexation itself enhances stratum corneum permeability relative to the free GHK tripeptide.

A 2025 review identified a critical measurement gap in liposomal GHK-Cu delivery: the mechanism of transport through skin for encapsulated versus free peptide remains incompletely characterized, and proposed CE-ICP-MS/MS methodology and Strat-M synthetic skin models as validated approaches for future studies ^[22].

Formulation chemistry studies indicate strong acid actives and ascorbic acid may reduce copper peptide stability in solution; copper peptide integrity in formulation may be reduced by AHAs, BHAs, and vitamin C. The clinical significance of these interactions in topical use is not fully established in peer-reviewed randomized controlled trials. These observations come from cosmetic chemistry literature and the stability section of the 2024 comprehensive review ^[5]. No dedicated incompatibility RCTs have been conducted.

Human data is limited to topical dermatological studies. The most cited: a 12-week collagen density study (70% improvement in treated subjects) ^[2]; a 12-week eye cream study in 41 women with improved skin density and reduced wrinkles ^[5]; an 8-week nanolipid carrier study achieving 55.8% wrinkle volume reduction ^[5]; and a 6-month hair growth pilot with the GHK/5-ALA combination (71.5-hair gain at 50 mg/mL versus 9.6 in placebo) ^[10]. No published randomized controlled trials for systemic injection in humans. No completed Phase 2/3 trials registered for GHK-Cu as a drug. Topical studies up to 12 weeks report good tolerability. Long-term systemic safety in humans has not been formally studied.